In 2017, Chong et al. [22] published the case of a patient with progressing DLBCL who was first treated with anti-CD19 CAR-modified T-cells and subsequently with an anti-PD-1 antibody. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.